Vascepa可预防高脂饮食诱导的葡萄糖不耐受、胰岛素抵抗和β细胞功能受损。

Vascepa protects against high-fat diet-induced glucose intolerance, insulin resistance, and impaired β-cell function.

作者信息

Al Rijjal Dana, Liu Ying, Lai Mi, Song Youchen, Danaei Zahra, Wu Anne, Mohan Haneesha, Wei Li, Schopfer Francisco J, Dai Feihan F, Wheeler Michael B

机构信息

Department of Physiology, University of Toronto, 1 King's College Circle, Medical Science Building Rm#3352, Toronto, ON, M5S 1A8, Canada.

Division of Advanced Diagnostics, Metabolism, Toronto General Research Institute, ON, Canada.

出版信息

iScience. 2021 Jul 28;24(8):102909. doi: 10.1016/j.isci.2021.102909. eCollection 2021 Aug 20.

Omega-3 fatty acid prescription drugs, Vascepa (≥96% eicosapentaenoic acid [EPA] ethyl ester) and Lovaza (46.5% EPA and 37.5% docosahexaenoic acid ethyl ester) are known therapeutic regimens to treat hypertriglyceridemia. However, their impact on glucose homeostasis, progression to type 2 diabetes, and pancreatic beta cell function are not well understood. In the present study, mice were treated with Vascepa or Lovaza for one week prior to six weeks of high-fat diet feeding. Vascepa but not Lovaza led to reduced insulin resistance, reduced fasting insulin and glucose, and improved glucose intolerance. Vascepa improved beta cell function, reduced liver triglycerides with enhanced expression of hepatic fatty acid oxidation genes, and altered microbiota composition. Vascepa has protective effects on diet-induced insulin resistance and glucose intolerance in mice.

ω-3脂肪酸处方药Vascepa（≥96%二十碳五烯酸[EPA]乙酯）和Lovaza（46.5% EPA和37.5%二十二碳六烯酸乙酯）是已知的治疗高甘油三酯血症的治疗方案。然而，它们对葡萄糖稳态、进展为2型糖尿病以及胰腺β细胞功能的影响尚不清楚。在本研究中，小鼠在高脂饮食喂养六周前用Vascepa或Lovaza治疗一周。Vascepa而非Lovaza可降低胰岛素抵抗、降低空腹胰岛素和血糖，并改善葡萄糖耐量。Vascepa改善了β细胞功能，降低了肝脏甘油三酯，增强了肝脏脂肪酸氧化基因的表达，并改变了微生物群组成。Vascepa对小鼠饮食诱导的胰岛素抵抗和葡萄糖耐量具有保护作用。